|Human embryonic stem cells: living on the edge.|
|Jump to Full Text|
|PMID: 23032268 Owner: NLM Status: MEDLINE|
|Vivian Gama; Mohanish Deshmukh|
Related Documents :
|23773718 - Therapy with autologous adipose-derived regenerative cells for the care of chronic ulce...
23243208 - β-adrenergic regulation of cardiac progenitor cell death versus survival and prolifera...
24704498 - Cholecystokinin octapeptide regulates the differentiation and effector cytokine product...
23293358 - A general approach for controlling transcription and probing epigenetic mechanisms: app...
16269858 - The current status of gene therapy in autologous transplantation.
21277328 - Activated t cells induce rapid cd83 expression on b cells by engagement of cd40.
|Type: Editorial Date: 2012-10-03|
|Title: Cell cycle (Georgetown, Tex.) Volume: 11 ISSN: 1551-4005 ISO Abbreviation: Cell Cycle Publication Date: 2012 Nov|
|Created Date: 2012-11-06 Completed Date: 2013-04-23 Revised Date: 2014-04-08|
Medline Journal Info:
|Nlm Unique ID: 101137841 Medline TA: Cell Cycle Country: United States|
|Languages: eng Pagination: 3905-6 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Caspases / metabolism
Cytochromes c / metabolism
Embryonic Stem Cells / cytology*, metabolism
Golgi Apparatus / metabolism
Mitochondria / metabolism
bcl-2-Associated X Protein / metabolism
|R01 GM078366/GM/NIGMS NIH HHS|
|0/bcl-2-Associated X Protein; 9007-43-6/Cytochromes c; EC 3.4.22.-/Caspases|
Journal ID (nlm-ta): Cell Cycle
Journal ID (iso-abbrev): Cell Cycle
Journal ID (publisher-id): CC
Publisher: Landes Bioscience
Copyright © 2012 Landes Bioscience
Print publication date: Day: 01 Month: 11 Year: 2012
pmc-release publication date: Day: 01 Month: 11 Year: 2012
Volume: 11 Issue: 21
First Page: 3905 Last Page: 3906
PubMed Id: 23032268
Publisher Id: 2012FT0761
Publisher Item Identifier: 22233
|Human embryonic stem cells : Living on the edge|
|Neuroscience Center; Department of Cell & Developmental Biology; University of North Carolina, Chapel Hill; Chapel Hill, NC USA
|*Correspondence to: Mohanish Deshmukh, Email: firstname.lastname@example.org
Despite intense investigation on apoptosis pathways, exactly how apoptosis is regulated in various primary cells remains understudied and continues to reveal unexpected mechanisms. While a strict regulation of apoptosis is critical for the long-term survival of postmitotic cells, mitotic cells need to maintain their ability to activate apoptosis rapidly, as they can be at continual risk of becoming cancerous.1 Therefore, cells must efficiently balance the need for having a primed apoptotic pathway vs. the risks associated with inadvertent cell death. This balance is particularly important during embryogenesis, where human embryonic stem (hES) cells proliferate rapidly and differentiate, leading to the development of an entire organism.2 While optimal hES cell survival is necessary for development, the ability of these cells to respond rapidly to DNA damage by apoptosis and maintain genomic integrity is also critical to prevent propagation of mutations in the developing embryo.3 Indeed, hES cells are known to be highly sensitive to DNA damage,4,5 and our recent results have uncovered a novel mechanism by which these cells are primed for rapid apoptosis.6
An essential mediator of apoptosis in mammalian cells is Bax, a proapoptotic member of the Bcl-2 family. In healthy cells, Bax is predominantly cytosolic and present in an inactive conformation. Apoptotic stimuli, such as DNA damage, result in the induction of BH3-only family proteins that promote Bax activation by conformational changes. Activated Bax then translocates to the mitochondria, where it inserts into the mitochondrial outer membrane, promoting the release of cytochrome c and resulting in caspase activation.7 Thus, Bax activation is a critical event in the commitment of cells to apoptosis.
We set out to decipher the mechanism underlying the rapid death response to etoposide-induced DNA damage in hES cells. This death was completely dependent on Bax. Surprisingly, we found Bax to be in its already active state in untreated hES cells.6 These results were unexpected, because, thus far, Bax activation has been seen only in cells that are actively undergoing apoptosis.8 However, we found no evidence of cell death in untreated hES cells that have activated Bax. Various elegant structural studies have shown that binding of the BH3-only activators to Bax induces conformational changes in Bax that expose the N terminus and the BH3 domain and mobilize the C terminus to insert into the mitochondrial outer membrane.9 Our results show that these steps of Bax activation are uncoupled in hES cells, with the N terminus of Bax already exposed and stabilized but without triggering of downstream structural events.
In cells undergoing apoptosis, active Bax localizes to the mitochondria to induce caspase activation.7 Unexpectedly, we found active Bax to be localized not at the mitochondria but at the Golgi (specifically at the trans-Golgi network) in untreated hES cells.6 These results identify hES cells as the first primary cell type to maintain Bax in its active state in the absence of cell death. Importantly, by localizing active Bax at the Golgi, hES cells appear to have developed a mechanism that allows them to maintain Bax in its active state but avoid the risk of spontaneous apoptosis associated with its mitochondrial localization.
To determine whether the constitutively active Bax localized to the Golgi enables hES cells to undergo rapid apoptosis, we examined whether active Bax changes localization after DNA damage. As early as 3 h after etoposide treatment, active Bax translocated from the Golgi to the mitochondria in hES cells undergoing apoptosis. Importantly, active Bax was maintained at the Golgi after etoposide treatment in p53-knockdown hES cells, indicating that p53 was required for the Golgi-to-mitochondria translocation of active Bax after DNA damage.6 Interestingly, high-resolution microscopy shows that the mitochondrial and Golgi networks in hES cells are very closely associated (almost intertwined), and this spatial proximity likely facilitates the rapid translocation of Bax from Golgi to mitochondria (unpublished results).
Finally, as hES cells have the potential to be differentiated into all cell lineages,10 we examined whether the constitutively active status of Bax seen in undifferentiated hES cells changed with differentiation. Interestingly, Bax was no longer present in its active state after just two days of differentiation. Consistent with the idea that the presence of active Bax in undifferentiated hES cells primes them for rapid apoptosis, the 2-day differentiated hES cells were also no longer acutely sensitive to DNA damage.6 These results illustrate how the apoptotic machinery undergoes dynamic changes to set apoptotic thresholds even at the earliest stages of hES cell differentiation (Fig. 1A).
These findings provide insight into how hES cells are primed to undergo rapid apoptosis, thus avoiding the accumulation of genomic mutations during a critical period of proliferation in early development. Many intriguing questions remain: what is the specific mechanism by which Bax is maintained in an active state in undifferentiated hES cells? How does active Bax localize to the Golgi? What is the molecular trigger that mobilizes active Bax from the Golgi to the mitochondria? How does the differentiation program reset the apoptotic sensitivity of hES cells? These investigations will undoubtedly uncover critical aspects of apoptosis regulation in cells and reveal key features of stem cell biology that may have significant impact for regenerative medicine.
Previously published online: www.landesbioscience.com/journals/cc/article/22233
|1.||Wright KM,et al. Cell CycleYear: 2006516162010.4161/cc.5.15.312916880745|
|2.||Thomson JA,et al. ScienceYear: 19982821145710.1126/science.282.5391.11459804556|
|3.||Stambrook PJ, et al. Preservation of Genomic Integrity in Mouse Embryonic Stem Cells, The Cell Biology of Stem Cells. In: Meshorer E, Plath K, eds.: Springer US, 2010:59-75.|
|4.||Momcilović O,et al. Stem CellsYear: 20092718223510.1002/stem.12319544417|
|5.||Grandela C,et al. Stem Cell ResYear: 200711162810.1016/j.scr.2007.10.00319383392|
|6.||Dumitru R,et al. Mol CellYear: 2012465738310.1016/j.molcel.2012.04.00222560721|
|7.||Tait SW,et al. Nat Rev Mol Cell BiolYear: 2010116213210.1038/nrm295220683470|
|8.||Youle RJ,et al. Nat Rev Mol Cell BiolYear: 20089475910.1038/nrm230818097445|
|9.||Gavathiotis E,et al. Cell CycleYear: 2011108687010.4161/cc.10.6.1503421325897|
|10.||Odorico JS,et al. Stem CellsYear: 20011919320410.1634/stemcells.19-3-19311359944|
Keywords: Keywords: apoptosis, Bax, ES cells, Golgi, cell death, DNA damage, p53, differentiation.
Previous Document: cIAP2 represses IKK?/?-mediated activation of MDM2 to prevent p53 degradation.
Next Document: Historical perspective on advanced drug delivery: How engineering design and mathematical modeling h...